A hyaluronic acid–methotrexate conjugate for targeted therapy of rheumatoid arthritis
Chemical Communications2014Vol. 50(57), pp. 7632–7632
Citations Over TimeTop 10% of 2014 papers
Jung Min Shin, Seol-Hee Kim, Thavasyappan Thambi, Dong Gil You, Jueun Jeon, Jong Oh Lee, Bong Youl Chung, Dong‐Gyu Jo, Jae Hyung Park
Abstract
In an effort to improve the therapeutic efficacy of methotrexate (MTX), we prepared the hyaluronic acid-MTX conjugate for targeted therapy of rheumatoid arthritis (RA). Owing to the pH-sensitive nature of the conjugate, MTX was rapidly released under the mildly acidic conditions, similar to the environment of inflamed synovial tissue in RA.
Related Papers
- → Radiographic progression in early rheumatoid arthritis: a 12-month randomized controlled study comparing the combination of cyclosporin and methotrexate with methotrexate alone(2003)70 cited
- Intrarticular methotrexate in the therapy of rheumatoid arthritis.(1989)
- → Acute erythroleukemia in a rheumatoid arthritis patient during low-dose methotrexate therapy(2004)8 cited
- → Methotrexate in Treatment of Rheumatoid Arthritis(1999)
- → HSD133 Factors Influencing Selection of First Add-on Disease-Modifying Therapy for Rheumatoid Arthritis after Starting Methotrexate(2022)